WHAT NEW RESEARCH IS SHOWING US ABOUT HIV VACCINE CANDIDATES

Federal investments in basic, biomedical, behavioral, and social science research have led to significant advances to the HIV vaccine field.

Read Article

We are CBC

The development of prophylactic vaccines against HIV is of paramount importance in the global efforts to halt the spread of the virus. The Clinical Bioreagent Center (CBC) it’s being utilized in the production of clinical-grade vaccine candidates based on the viral envelope protein (EnV). Our goal is to streamline the process development pipeline of a promising biotherapeutic from lead to clinic. The CBC develops tailored analytical tools for a wide array of biological products in a good manufacturing practice environment.

Recent HIV Vaccine News

Monkey Trial show Promising Results

Go to original article > Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here, we immunized macaques with an HIV envelope trimer, either alone to induce nAbs, or together with a heterologous viral vector regimen to elicit nAbs and…

Details
Logo-nachrs-med
Logo Nief